We are live on ! Find out more
ALDX icon

Aldeyra Therapeutics
ALDX

35 hedge funds and large institutions have $66.4M invested in Aldeyra Therapeutics in 2017 Q3 according to their latest regulatory filings, with 13 funds opening new positions, 15 increasing their positions, 5 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

333% more first-time investments, than exits

New positions opened: 13 | Existing positions closed: 3

200% more repeat investments, than reductions

Existing positions increased: 15 | Existing positions reduced: 5

91% more capital invested

Capital invested by funds: $34.7M → $66.4M (+$31.7M)

35% more funds holding

Funds holding: 26 → 35 (+9)

0.05% more ownership

Funds ownership: 49.16% → 49.2% (+0.05%)

Holders
35
Holders Change
+9
Holders Change %
+34.62%
% of All Funds
0.87%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
13
Increased
15
Reduced
5
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
Millennium Management
Millennium Management
New York
+$2.32M
2
6CM
683 Capital Management
New York
+$1.62M
3
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$1.44M
4
PA
Perceptive Advisors
New York
+$1.04M
5
SFM
Sphera Funds Management
Israel
+$878K

Top Sellers

1
SM
Sabby Management
Florida
-$454K
2
Fidelity Investments
Fidelity Investments
Massachusetts
-$225K
3
WMSA
Weiss Multi-Strategy Advisers
New York
-$62.7K
4
BlackRock
BlackRock
New York
-$9.8K
5
NFG
Next Financial Group
Texas
-$9K
Name Holding Trade Value Shares
Change 		Change in
Stake
PA
1
Perceptive Advisors
New York
$22.2M +$1.04M +200,000 +7%
Fidelity Investments
2
Fidelity Investments
Massachusetts
$11.6M -$225K -43,000 -3%
SFM
3
Sphera Funds Management
Israel
$7.52M +$878K +168,200 +19%
6CM
4
683 Capital Management
New York
$6.02M +$1.62M +310,421 +59%
Adage Capital Partners
5
Adage Capital Partners
Massachusetts
$5.4M +$1.44M +275,000 +58%
Millennium Management
6
Millennium Management
New York
$3.92M +$2.32M +444,585 +442%
Vanguard Group
7
Vanguard Group
Pennsylvania
$3.39M +$869K +166,398 +55%
KCM
8
Knoll Capital Management
Florida
$893K – – –
HP
9
Hikari Power
Japan
$777K – – –
Renaissance Technologies
10
Renaissance Technologies
New York
$613K +$156K +29,900 +54%
Geode Capital Management
11
Geode Capital Management
Massachusetts
$547K +$94.7K +18,140 +31%
MIM
12
Monashee Investment Management
Massachusetts
$504K – – –
TSS
13
Two Sigma Securities
New York
$365K +$265K +50,728 New
WMSA
14
Weiss Multi-Strategy Advisers
New York
$360K -$62.7K -12,000 -19%
WC
15
Woodstock Corp
Massachusetts
$348K +$253K +48,393 New
AAP
16
Ardsley Advisory Partners
Connecticut
$285K +$131K +25,000 +172%
BlackRock
17
BlackRock
New York
$271K -$9.8K -1,877 -5%
HighTower Advisors
18
HighTower Advisors
Illinois
$214K +$155K +29,650 New
EMG
19
Ellington Management Group
Connecticut
$168K +$122K +23,300 New
Squarepoint
20
Squarepoint
New York
$159K +$115K +22,070 New
Bank of New York Mellon
21
Bank of New York Mellon
New York
$134K +$97K +18,570 New
State Street
22
State Street
Massachusetts
$133K +$96.6K +18,500 New
Northern Trust
23
Northern Trust
Illinois
$124K +$11.8K +2,268 +15%
DS
24
DRW Securities
Illinois
$86K +$62.7K +12,000 New
Jane Street
25
Jane Street
New York
$79K +$57.2K +10,961 New
1
2

ALDX Hedge Fund Activity: Q3 2017 in Review

35 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Aldeyra Therapeutics (ALDX) for Q3 2017, worth a combined $66.4M — up 91% from $34.7M a quarter earlier.

Buyers outnumbered sellers: 13 funds opened new ALDX positions and 3 closed out — a net gain of 10 holders — while 15 added to existing stakes and 5 trimmed.

The largest buyer was Millennium Management, adding an estimated $2.32M. The largest seller was Sabby Management, exiting entirely with an estimated $454K sold.

  • 35 institutional investors held Aldeyra Therapeutics (ALDX) as of Q3 2017, up from 26 in Q2 2017.
  • Funds reported $66.4M of Aldeyra Therapeutics stock for Q3 2017, up 91% quarter-over-quarter.
  • 13 funds opened new Aldeyra Therapeutics positions in Q3 2017 and 3 closed out, a net change of +10 holders.
  • The largest Aldeyra Therapeutics buyer in Q3 2017 was Millennium Management, an estimated $2.32M added.
  • The largest Aldeyra Therapeutics seller in Q3 2017 was Sabby Management, an estimated $454K sold.

Based on aggregated 13F filings for Q3 2017.